沙库巴曲缬沙坦在腹膜透析患者中的药代动力学与药效学
本研究为开放标签横断面研究,纳入40例合并高血压或心力衰竭的腹膜透析患者,评估沙库巴曲缬沙坦的药代动力学与药效学。结果显示腹膜透析和残余肾功能对LBQ657清除贡献较小,100 mg每日两次方案安全有效。
要点
- 腹膜透析和残余肾功能对LBQ657清除贡献较小。
- 100 mg每日两次沙库巴曲缬沙坦在合并高血压或心衰的腹膜透析患者中安全有效。
- 服药后msSBP和msDBP分别较基线下降19.25±10.32 mmHg和10.10±8.00 mmHg。
核心结论
- 腹膜透析和残余肾功能对LBQ657的清除贡献较小。
- 100 mg每日两次沙库巴曲缬沙坦在合并高血压或心衰的腹膜透析患者中安全有效。
研究设计与样本
- 开放标签横断面研究,纳入40例诊断为高血压或NYHA II-IV级心力衰竭的腹膜透析患者。
- 采用超高效液相色谱串联质谱法测定血浆、尿液和腹膜透析液中缬沙坦、沙库巴曲和沙库巴曲拉(LBQ657)浓度。
- 设置三个治疗队列:50 mg每日两次、100 mg每日一次和100 mg每日两次。
主要发现
- 40例患者中27例(67.5%)合并高血压,4例(10%)合并心衰,9例(22.5%)同时合并高血压和心衰。
- 100 mg每日两次组血浆最大药物浓度:缬沙坦1995±1499 ng/mL,沙库巴曲171±148 ng/mL,LBQ657 13686±7418 ng/mL。
- LBQ657的24小时回收率在尿液中为3.77%,在腹膜透析液中为2.23%。
- 服用沙库巴曲缬沙坦后msSBP和msDBP分别较基线下降19.25±10.32 mmHg和10.10±8.00 mmHg。
- NT-proBNP较基线下降1436.50(0.00-18198.00),LVEF较基线增加5.00(-0.25至9.25)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is little information on the pharmacokinetics and pharmacodynamics of sacubitril/valsartan (SV) in patients undergoing peritoneal dialysis (PD) complicated with hypertension or heart failure (HF). This study was designed to evaluate the pharmacokinetics and pharmacodynamics of SV in PD patients with complications of hypertension or HF. METHODS: This was an open-label and cross-sectional study investigating PD patients diagnosed with hypertension or New York Heart Association Class II-IV HF. The concentrations of valsartan, sacubitril and sacubitrilat (LBQ657) were measured by ultra-performance liquid chromatography tandem mass spectrometry in plasma, urine and peritoneal dialysate samples. Pharmacodynamics were evaluated by comparing changes in mean sitting systolic blood pressure (msSBP), mean sitting diastolic blood pressure (msDBP), mean sitting heart rate, N-terminal-pro B-type natriuretic peptide (NT-proBNP) and left ventricular ejection fraction (LVEF). RESULTS: Forty patients with PD were enrolled including 27 (67.5%) patients with hypertension, 4 (10%) patients with HF and 9 (22.5%) patients with both hypertension and HF. This study included three treatment cohorts: 50 mg twice daily (BID), 100 mg once daily and 100 mg BID. The plasma maximum drug concentrations in the 100 mg BID group were 1995 ± 1499 ng/mL for valsartan, 171 ± 148 ng/mL for sacubitril and 13 686 ± 7418 ng/mL for LBQ657. The 24-h recovery rate of LBQ657 was 3.77% in urine and 2.23% in peritoneal dialysate. After taking SV, msSBP and msDBP decreased by 19.25 ± 10.32 mmHg and 10.10 ± 8.00 mmHg from baseline, respectively. NT-proBNP decreased by 1436.50 (0.00-18 198.00) from baseline, while LVEF increased by 5.00 (-0.25 to 9.25) from baseline after SV treatment. CONCLUSIONS: PD and residual renal function contributed only to a minor degree to the elimination of LBQ657. Additionally, a dose of 100 mg BID SV is safe and effective in patients with PD with complications of hypertension or HF.
引用
- He Y, Jin Y, Xue H, et al. Pharmacokinetics and pharmacodynamics of sacubitril/valsartan in peritoneal dialysis patients. Nephrol Dial Transplant. 2023. PMID: 36787894. doi:10.1093/ndt/gfad038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。